Hypertension drug developer Retension (RTSN.US) IPO priced at $11-13 per share, aiming to raise $40 million.
Retension Pharmaceuticals (RTSN.US) announced the terms of its initial public offering (IPO) on Monday.
According to Golden Ten Data APP, US hypertension drug developer Retension Pharmaceuticals (RTSN.US) announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 3.3 million shares at a price range of $11 to $13 per share, raising $40 million. Based on the midpoint of the offering price range, Retension's fully diluted market capitalization will reach $108 million.
Retension was founded in 2023 and is a clinical-stage biopharmaceutical company currently focused on developing a single product, RTN-001. This is a once-daily, oral PDE-5 inhibitor for the treatment of uncontrolled hypertension and resistant hypertension. First-generation PDE-5 inhibitors (such as Viagra) never achieved meaningful blood pressure-lowering effects. The company believes this is because such drugs have difficulty fully penetrating the central vascular system rich in smooth muscle, whereas RTN-001 has been redesigned to improve bioavailability and increase its distribution within these tissues.
This drug was initially developed by Surface Logix, then subsequently by Nano Terra, Kadmon, and Sanofi, until the current team reacquired its license in 2023, bringing data from 9 completed trials, including two phase 2 trials. In October 2025, the company started a phase 2b dose exploration trial involving 280 patients, with about 40% of patients enrolled so far, and preliminary data expected to be released in the first half of 2027.
Retension plans to list on Nasdaq under the stock code "RTSN", with Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. acting as joint underwriters for the transaction. Pricing is expected during the week of October 5, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Crescent Energy shares fall as it raises 1.1 billions in equity to acquire Devon
October 9 - Crescent Energy (CRGY.N) shares fell 1% to $12.88 in premarket trading on Friday after the company priced and completed a $1 billion follow-on offering related to an acquisition. The Houston, Texas-based shale oil and gas producer announced late Thursday that it would issue 80 million shares at $12.50 each, representing a 3.9% discount to its most recent closing price. CRGY will use the net proceeds from the offering to help fund its $4.2 billion acquisition of Devon Energy's (DVN.N) Eagle Ford oil and gas assets. A KKR (KKR.N) affiliate, which owns about 7.9% of CRGY, will subscribe to 40 million new shares. JPMorgan, KKR Capital Markets, Raymond James, Evercore, and Wells Fargo Securities will act as joint book-running managers for the offering. CRGY has approximately 330.4 million shares outstanding, with a market capitalization of $4.3 billion. The stock closed down 3.4% on Thursday, narrowing its year-to-date gain to 55%. According to data from London Stock Exchange Group (LSEG), 13 out of 16 analysts rate the stock as "strong buy" or "buy," 2 rate it "hold" and 1 recommends "sell," with a median price target of $18.50. DVN's shares were down 1.4% in premarket trading at $48.22. DVN rose 2.2% on Thursday, bringing its cumulative gain in 2026 to about 34%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
BUZZ - Reports of iPhone production cuts send Apple shares lower
October 9 – According to Nikkei Asia (link), Apple has asked its suppliers to cut production of the new iPhone 18 Pro model due to weak demand, resulting in Apple (AAPL.O) shares falling 1.8% in premarket trading to $334.21. The report states that, against the backdrop of soaring memory chip costs and rising prices, the component orders for October have been reduced by at least 15% compared to initial requirements. Apple has not yet responded to a Reuters request for comment. The current stock price is about 1% lower than the all-time intraday high of $345.34 reached on September 22. According to data compiled by the London Stock Exchange Group (LSEG), the average rating from 43 analysts covering the stock is "Buy," with a median target price of $330. (For the convenience of non-English speakers, Reuters provides automated translations of its report into several other languages. As automated translations may contain errors or lack the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for reader convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
Citi maintains a “Neutral” rating on DocuSign (DOCU.O): IAM platform migration shows initial effectiveness, double-digit growth still needs "validation"
Citi published a research report maintaining a "Neutral" rating on the e-signature and agreement cloud platform DocuSign, with a target price of $72.
Market Chatter: Mastercard CEO Says Cross-Border Payments Is Currently Stablecoin's Best Use Case
07:14 AM EDT, 10/09/2026 (MT Newswires) -- Mastercard (MA) Chief Executive Officer Michael Miebach said that cross-border payments currently present the best use case for stablecoins, Bloomberg reported Friday, citing an interview. Mastercard is interested in stablecoins for moving money rather than as an investment, Miebach said, according to the report. The company is an investor in a new firm called Open Standard, which recently issued a US dollar-pegged stablecoin, the report added. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
